InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Merger or Acquisition (September 2021)
16 slides from InMed Pharmaceuticals's merger presentation, September 2021
Slide 1: InMed Pharmaceuticals Acquiring BayMedica
InMed Pharmaceuticals Acquiring BayMedica Establish market leadership in the manufacturing and development of rare cannabinoids September 2021 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid p
Slide 3: Create shareholder value by combining complementary business models
Create shareholder value by combining complementary business models A Cannabinoid Pharmaceutical Company Manufacturer and Supplier to the Consumer Health & Wellness Market • Pharmaceutical-grade, proprietary approach for synthesized • Proprietary manufacturing platforms for naturally occurring rare
Slide 4: Why This Acquisition is Transformational
Why This Acquisition is Transformational Create a pure-play cannabinoid (CB) company with unparalleled, multi-faceted manufacturing capacity and strong clinical expertise Create Market Leader in Leader in a variety of cannabinoid manufacturing approaches Manufacturing Increase Commercial Substantial
Slide 5: Unparalleled Cannabinoid Manufacturing Expertise
Unparalleled Cannabinoid Manufacturing Expertise Chemical IntegraSyn™ Synthesis Biosynthesis • Utilizes very high efficiency, biosynthesis • Preferred for CBs with simple structure and • Preferred for complex structures at very derived enzyme CB analog R&D large scale • Flexibility to shift from pro
Slide 6: Combined Manufacturing Expertise to Support Target End Markets
Combined Manufacturing Expertise to Support Target End Markets Production of rare cannabinoids used for pharmaceutical and consumer health and wellness Pharmaceutical Cannabinoid Consumer Health Manufacturing & Wellness Expertise Pharmaceutical-grade Multiple cannabinoid manufacturing Immediate and
Slide 7: Extensive Combined Assets, Capabilities, and Commercial Potential
Extensive Combined Assets, Capabilities, and Commercial Potential Leading Manufacturing Know-How Large Market Presence • Sector-leading position in several CB • Speed & access to commercial markets / revenues manufacturing methods; able to select most • Existing B2B sales in the US health/wellness m
Slide 8: Extensive Patent Protection for Combined Company
Extensive Patent Protection for Combined Company Major opportunity for expansion of patent portfolio of new chemical entities • A growing library of new analogs targeting diverse diseases • Patent applications covering the biosynthetic pathway and semi-synthetic production of both natural cannabinoi
Slide 9: BayMedica Manufacturing Expertise in Rare CBs for Consumer Health & Wellness
BayMedica Manufacturing Expertise in Rare CBs for Consumer Health & Wellness Advancing multiple rare cannabinoids to commercialization 100+ Rare Cannabinoids Stage of Requires synthetic manufacturing Development < 1% for commercial viability Major Cannabinoids 2-20% CBC Commercial Easy to extract fr
Slide 10: Cannabinoid Synthesis Demand Expected to Drive Exponential Market Growth
Cannabinoid Synthesis Demand Expected to Drive Exponential Market Growth 120 $115B 100 80 Global cannabinoid synthesis market $60B estimated to grow 60 from $10B in 2025 to $115B by 2040 40 $30B 20 $10B $200M 0 Source: Raymond James, Sept 2020 2020 2025 2030 2035 2040 10
Slide 11: Growing Revenue from Current Commercial Product – Cannabichromene (CBC)
Growing Revenue from Current Commercial Product – Cannabichromene (CBC) Multiple Wholesale Markets in Features of BayMedica ProDiol® CBC Consumer Health and Wellness ● Global leader in CBC large batch supply Prodiol® CBC ● Non-intoxicating; not scheduled by DEA ls Sup tica ple ceu ● Consumer health
Slide 12: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise Eric A. Adams, MIBS Shane Johnson, MD Chief Executive Officer SVP and General Manager BayMedica 30+ years of experience in global biopharma leadership 20+ years strategic planning/ execution with LEK Consulting in BusDev, S&M with enGene, QLT, Abbot
Slide 13: Financial Snapshot
Financial Snapshot INM Cash and Short-term Investments (Mar 31, 2021)* $9.5 M1 Shares I/O 12.1 M2 Options (Mar 31, 2021) 0.9 M Warrants 6.5 M Fully Diluted Shares, September 10, 2021 19.5M4 Previous Close (2021-09-10) US$2.11 52-week High3 US$8.94 52-week Low3 US$2.02 Avg. Daily Volume (Trailing 50
Slide 14: Combined Short-term Milestones to Drive Shareholder Value
Combined Short-term Milestones to Drive Shareholder Value Manufacturing • Continue to drive revenues from current ProDiol® CBC product • Launch several new cannabinoids into B2B Consumer Packaged Goods space • Integrate manufacturing teams and technical know-how to prioritize next projects Drug Deve
Slide 15: Long-term Growth Strategy
Long-term Growth Strategy Advancing a global leader in the manufacturing and development of rare cannabinoids Accelerate Launch new cannabinoids into the consumer & health and Revenue Growth wellness space Advance Drug Deliver clinically proven CBN-based drugs for unmet medical Development needs in
Slide 16: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Senior Director, Investor Relations cclancy@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Merger or Acquisition (September 2021) on 6ix